COVID-19: EMA Makes Scientific Advice Free & Fast For Drug, Vaccine Developers
The European Medicines Agency has waived its fee for scientific advice for developers of potential vaccines and treatments for the coronavirus
You may also be interested in...
A new legislative proposal is seeking to empower the European Medicines Agency in tracking potential shortages of drugs and medical devices and enable the agency to play a greater role in coordinating clinical trials and vaccine research during health emergencies.
From speeding up PIP agreements to starting rolling reviews, the European Medicines Agency has explained how it is accelerating its regulatory procedures for COVID-19 treatments and vaccines.
The European Patent Office has adjusted the starting date of its transitional measures for applicants that want their patent to have unitary effect under the coming Unified Patent Court system.